MedTrace Logo

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

NCT00652496 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 249

Last updated 2008-04-03

No results posted yet for this study

Summary

This study evaluates the safety and efficacy of different formulations of bimatoprost ophthalmic solution compared with Bimatoprost 0.03% once-daily in patients with glaucoma or ocular hypertension. One of the test formulations was given to one eye and bimatoprost 0.03% given to the fellow eye of each patient

Conditions

Interventions

DRUG

Bimatoprost 0.01% ophthalmic solution

One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop

DRUG

Bimatoprost 0.015% formulation 1 ophthalmic solution

One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop

DRUG

Bimatoprost 0.015% formulation 2 ophthalmic solution

One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop

DRUG

Bimatoprost 0.02% ophthalmic solution

One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop

DRUG

Bimatoprost 0.03% ophthalmic solution

Bimatoprost 0.03% ophthalmic solution, one drop in one eye, once daily in the morning for 4 consecutive days, the other eye received one drop of any of the 4 study drugs

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2005-05-31
Completion
2005-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00652496 on ClinicalTrials.gov